原发性胆汁性肝硬化的药物治疗进展  

Drug therapy of primary biliary cirrhosis

作　　者：张华伟[1] 张艳[2] 杨镜[2] 徐凌[2] 卢洁[2] 郭传勇[2] 

机构地区：[1]苏州大学附属第一医院消化科,苏州215006 [2]同济大学附属第十人民医院消化科,上海200072

出　　处：《世界临床药物》2014年第4期253-256,共4页World Clinical Drug

基　　金：国家自然科学基金(编号:81270515)

摘　　要：原发性胆汁性肝硬化(PBC)是一种病因未明的慢性进行性胆汁淤积性肝脏疾病。熊去氧胆酸是目前最具循证医学支持的PBC治疗药物,但约40%PBC患者对熊去氧胆酸治疗应答不良。本文综述糖皮质激素、免疫抑制剂、贝特类降脂药、抗逆转录病毒药物以及利妥昔单抗等临床常用药物和某些临床有可能选用的联合治疗方案。Primary biliary cirrhosis （PBC） is an unknown etiological chronic progressive cholestatic liver disease. Currently, ursodeoxycholic acid is the most evidence-based medications for PBC. However, approximately 40% of patients with PBC respond incompletely to treatment with ursodeoxycholic acid. Therefore, several new medications are being studied in the treatment of＂poorly responsive＂ PBC, including glucocorticoids, immunosuppressants, fibrates, antiretroviral, rituximab, and some possible combination therapies.

关 键 词：原发性胆汁性肝硬化 药物治疗 熊去氧胆酸 

分 类 号：R575.22[医药卫生—消化系统] R975.5[医药卫生—内科学]